Global Cancer Diagnostics Market 2022-2028

Cancer is a disease in which some of the body's cells grow uncontrollably and spread to other parts of the body. It is the second leading cause of death globally, accounting for an estimated 9.6 million deaths, or one in six deaths, in 2018. Between 30% and 50% of cancer deaths could be prevented by modifying or avoiding key risk factors and implementing existing evidence-based prevention strategies. Early diagnosis improves cancer outcomes by providing care at the earliest possible stage and is therefore an important public health strategy in all settings. According to latest analysis by publisher, the global cancer diagnostics market is poised to grow by USD 75 billion during 2022-2028, progressing at a CAGR of 6.2% during the forecast period. The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global cancer diagnostics market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the cancer diagnostics industry. This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the type, disease indication, end user, and region. The global market for cancer diagnostics can be segmented by type: laboratory tests, genetic tests, imaging, endoscopy, biopsy, others. Cancer diagnostics market is further segmented by disease indication: blood cancer, breast cancer, cervical cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, others. Based on end user, the cancer diagnostics market is segmented into: hospitals and clinics, diagnostic laboratories, diagnostic imaging centers, others. On the basis of region, the cancer diagnostics market also can be divided into: North America, Asia Pacific, Europe, Rest of the World (ROW). By type: - laboratory tests - genetic tests - imaging - endoscopy - biopsy - others By disease indication: - blood cancer - breast cancer - cervical cancer - colorectal cancer - kidney cancer - liver cancer - lung cancer - ovarian cancer - pancreatic cancer - prostate cancer - skin cancer - others By end user: - hospitals and clinics - diagnostic laboratories - diagnostic imaging centers - others By region: - North America - Asia Pacific - Europe - Rest of the World (ROW) The global cancer diagnostics market report offers detailed information on several market vendors, including Abbott Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, GE Healthcare, Hologic, Inc., Illumina, Inc., Koninklijke Philips N.V., Merck & Co., Inc., Qiagen N.V., Siemens Healthineers AG, Thermo Fisher Scientific, Inc., among others. *REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES Historical & Forecast Period This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year. Scope of the Report - To analyze and forecast the market size of the global cancer diagnostics market. - To classify and forecast the global cancer diagnostics market based on type, disease indication, end user, region. - To identify drivers and challenges for the global cancer diagnostics market. - To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global cancer diagnostics market. - To identify and analyze the profile of leading players operating in the global cancer diagnostics market. Why Choose This Report - Gain a reliable outlook of the global cancer diagnostics market forecasts from 2022 to 2028 across scenarios. - Identify growth segments for investment. - Stay ahead of competitors through company profiles and market data. - The market estimate for ease of analysis across scenarios in Excel format. - Strategy consulting and research support for three months. - Print authentication provided for the single-user license.